Oncology · HER2-positive solid tumours • Jun 2, 2026

Enhertu's EU Approval Could Redefine HER2 Treatment Landscape

Assessment confidence: 86% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This approval could enhance AstraZeneca and Daiichi Sankyo's market position in oncology, particularly in the HER2-targeted therapy space. Regulatory context from FDA (FDA Grants Seventh Approval under the National Priority Voucher Pilot Program) supports the near-term read. Assessment grounded in 5 ranked evidence items (4 high-relevance).

Strategic Assessment

This approval could enhance AstraZeneca and Daiichi Sankyo's market position in oncology, particularly in the HER2-targeted therapy space. The strongest clinical anchor is Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her2). In her2, 1 regulatory and 0 competitive items passed relevance filtering for Enhertu recommended for EU approval in HER2+ metastatic solid tumours.

Competitive Pressure

The most relevant competitive pressure comes from If approved, Enhertu will be the first HER2-directed therapy with a tumour agnostic indication in the EU, potentially setting a new standard in treatment..

Regulatory Outlook

Regulatory risk is concentrated around FDA Grants Seventh Approval under the National Priority Voucher Pilot Program (FDA). Regulatory pathway relevance (approval).

Key Risks

Signal severity is high — leadership review is warranted.

Key Opportunities

Upside for Enhertu recommended for EU approval in HER2+ metastatic solid tumours may improve if A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Enhertu recommended for EU approval in HER2+ metastatic solid tumours may improve if ShortStop-HER2: 12 Months vs. (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Enhertu recommended for EU approval in HER2+ metastatic solid tumours may improve if Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (ClinicalTrials.gov) delivers favorable follow-through.
FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
This approval could enhance AstraZeneca and Daiichi Sankyo's market position in oncology, particularly in the HER2-targeted therapy space.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval decision from the European Commission and subsequent market access strategies.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
FDAmedium relevance
Regulatory pathway relevance (approval)
[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)
PMDAlow relevance
Regulatory pathway relevance (approval)
FDA Expands AI Capabilities and Completes Data Platform Consolidation
FDAlow relevance
Weak alignment to signal sub-indication and entities
[KOKUSAI]Registration for the ASEAN-Japan Medical Devices Regulatory Symposium is now open.
PMDAlow relevance
Weak alignment to signal sub-indication and entities
Draft rare disease therapies regulatory framework
MHRAlow relevance
Weak alignment to signal sub-indication and entities
CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
FDAlow relevance
Weak alignment to signal sub-indication and entities
Transparency data: MHRA Performance Data
MHRAlow relevance
Weak alignment to signal sub-indication and entities

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
ClinicalTrials.govlow relevance
Patient population match (metastatic)
A Study of ASP1012 in Adults With Solid Tumors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities

No evidence in this category.

Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
TFPI2 in tumor metastasis: a double-edged sword with clinical implications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedlow relevance
Broad oncology match without sub-indication specificity
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity

Related Signals

Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Regulatory Approval

Related Regulatory Precedents

PMDA
[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)
PMDA document relevant to the signal.
Source
FDA
FDA AP — ENHERTU (SUPPL)
Application BLA761139. Sponsor: DAIICHI SANKYO. Submission status: AP. Submission type: SUPPL. Review priority: PRIORITY. Active ingredients: FAM-TRASTUZUMAB DERUXTECAN-NXKI.
Source
FDA
FDA AP — ONTRUZANT (SUPPL)
Application BLA761100. Sponsor: SAMSUNG BIOEPIS CO LTD. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB-DTTB.
Source
FDA
FDA AP — HERCEPTIN HYLECTA (SUPPL)
Application BLA761106. Sponsor: GENENTECH INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB AND HYALURONIDASE-OYSK.
Source
FDA
Novel Drug Approvals for 2026
Novel Drug Approvals for 2026
Source

← All insights